Ninety One UK Ltd Has $26.91 Million Position in Stryker Co. (NYSE:SYK)

Ninety One UK Ltd reduced its position in shares of Stryker Co. (NYSE:SYK) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,747 shares of the medical technology company’s stock after selling 3,215 shares during the period. Ninety One UK Ltd’s holdings in Stryker were worth $26,913,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Alhambra Investment Management LLC increased its stake in Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after acquiring an additional 29 shares during the period. Capital & Planning LLC increased its stake in Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after acquiring an additional 29 shares during the period. Concord Wealth Partners increased its stake in Stryker by 2.2% during the 4th quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 30 shares during the period. Avestar Capital LLC increased its stake in Stryker by 1.1% during the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after acquiring an additional 31 shares during the period. Finally, Union Savings Bank increased its stake in Stryker by 1.0% during the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after acquiring an additional 31 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by corporate insiders.

Stryker Trading Up 1.7 %

NYSE SYK opened at $399.01 on Thursday. The business’s 50-day moving average price is $376.87 and its two-hundred day moving average price is $364.00. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market capitalization of $152.11 billion, a PE ratio of 51.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm posted $3.46 EPS. On average, analysts expect that Stryker Co. will post 13.5 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.84%. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SYK shares. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Robert W. Baird lifted their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus lifted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.